Back to Search

DAWN

Day One Biopharmaceuticals, Inc. Common Stock
Data: 2026-04-22
$21.53
Price
0.19%
Change
$21.53
52W High
$5.64
52W Low
Buy/Sell Forecast Trendline Why Moving Charts Options

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

Quick Stats

58.6

AI Score

HOLD

1.07

Volume Ratio

Next Earnings

20

+ve Days (30d)

9

-ve Days (30d)

DAWN Stock Summary

Last updated

DAWN is currently trading at $21.53, positioned below its 200-day moving average of $, suggesting bearish momentum. The stock has a 52-week range of $5.635 to $21.53.

Technical Analysis: The 50-day moving average stands at $, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads , suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is , which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates DAWN at 58.6/100 with a HOLD recommendation.

DAWN Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

DAWN Price vs Max Options Open Interest
DAWN Max Change In Options Open Interest

DAWN Options - Sort by Max open Interest (near term)

22nd May 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

DAWN Daily Out of Money Options - Sort by Max open Interest (near term)

22nd May 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

DAWN Daily In the Money Options - Sort by Max open Interest (near term)

22nd May 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

DAWN Most Active Options by Volume(near term)

22nd May 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI		 Ask PC Delta Vega Volatility % change Track

Day One Biopharmaceuticals, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

DAWN Moving Averages Analysis

DAWN (Day One Biopharmaceuticals, Inc. Common Stock) Simple Moving Averages

Moving Averages are last updated

Days MA

DAWN Fundamental Analysis

P/E (Forward) 0
P/E (Trailing) --
Market Cap ($) 2.2 billion
Earnings/Share ($) -1.04
Net Proft Margin (%) -0.6785
Dividend/Share ($) --
EPS Estimate Current Year ($) -0.7551
EPS Estimate Next Year ($) -0.0427
WallStreet Target Price ($) 21.5
Most Recent Quarter